- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
NANOBIOTIX (Euronext : NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2013.
of which :
*over the second quarter of 2012, the company recorded no revenue
As in previous quarters, revenue recorded during the second quarter of 2013 corresponds to the pro rata share of the first payment received by the company within the framework of the licensing contract signed with PharmaEngine, the Taiwan-based biopharmaceutical company, in August 2012, which covers the development and commercialization of NBTXR3 in the Asia-Pacific region. This upfront payment amounts to €810,640, generating a product of €45,847 for the period and totalling €92,328 for the first semester in 2013. The invoicing of services totalled €2,722 for the period. In total, revenue for the second quarter amounts €48,569. Revenue for the first half of 2013 is €95,050 which is fully in line with Company expectations.
Nanobiotix remains focused on the clinical development of its lead products where commercialization is planned for 2017. Recent positive news flow, especially in June, indicates the successful implementation of Nanobiotix's strategy in line with the Company's development plan. In June, Nanobiotix published encouraging preliminary results for lead product NBTXR3 with clinical proof of concept, safety and security of the intratumoral injection in patients with soft tissue sarcoma. In parallel, Nanobiotix has received approval from ANSM to start a new clinical trial for NBTXR3 in head and neck cancer patients, a major concern in terms of public health in European countries and across Asia. Nanobiotix has also initiated the preclinical development of NBTX-IV, the second product from the NanoXray pipeline, through collaboration with the US National Cancer Institute (NCI).
Results for the first half of 2013, on August 30, 2013
Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product, NBTXR3 based on NanoXray, is currently under clinical development for soft tissue sarcoma. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The Company is based in Paris, France.
Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).
For more information, please click here
+33 (0)1 40 26 07 55
and investors relations
+33 (0)1 44 71 98 53
Media relations (France)
Nadège Le Lezec
+33 (0)1 53 63 27 27
+33 (0)6 88 20 35 59
Media relations (Outside France)
Melanie Toyne Sewell
Donia Al Saffar
+44 (0) 207 457 2020
Copyright © NanobiotixIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
New approach to determining how atoms are arranged in materials August 25th, 2016
Designing ultrasound tools with Lego-like proteins August 29th, 2016
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
Meteorite impact on a nano scale August 29th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016
Nanobiotix revenue for Q2 2016 July 14th, 2016